Compagnie Lombard Odier SCmA’s Karyopharm Therapeutics KPTI Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-55,312	Closed	-$8.73M	–	660
2021 Q1	$8.73M	Buy	+55,312	New	+$11.7M	0.19%	87
2017 Q1	–	Sell	-120	Closed	-$17K	–	791
2016 Q4	$17K	Hold	120	–	–	﹤0.01%	720
2016 Q3	$18K	Hold	120	–	–	﹤0.01%	796
2016 Q2	$12K	Hold	120	–	–	﹤0.01%	817
2016 Q1	$16K	Hold	120	–	–	﹤0.01%	845
2015 Q4	$24K	Hold	120	–	–	﹤0.01%	782
2015 Q3	$19K	Hold	120	–	–	﹤0.01%	702
2015 Q2	$49K	Hold	120	–	–	﹤0.01%	646
2015 Q1	$55K	Buy	+120	New	+$51.7K	﹤0.01%	772

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Compagnie Lombard Odier SCmA's KPTI Position: Q2 2021 in Review

Compagnie Lombard Odier SCmA sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 55,312 shares — an estimated $8.73M sold.

Compagnie Lombard Odier SCmA first reported a position in KPTI in Q1 2015 and held it in 9 quarters. The position peaked at $8.73M in Q1 2021. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

Compagnie Lombard Odier SCmA reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 55,312 Karyopharm Therapeutics shares in Q2 2021, an estimated $8.73M.
Compagnie Lombard Odier SCmA first reported a position in Karyopharm Therapeutics in Q1 2015 and held it in 9 quarters.
Compagnie Lombard Odier SCmA's Karyopharm Therapeutics position peaked at $8.73M in Q1 2021.
153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2021, filed 15 Jul 2021.